CN106176854B - Application of Babaodan in preparing medicine for preventing alcoholic liver injury - Google Patents
Application of Babaodan in preparing medicine for preventing alcoholic liver injury Download PDFInfo
- Publication number
- CN106176854B CN106176854B CN201510225416.8A CN201510225416A CN106176854B CN 106176854 B CN106176854 B CN 106176854B CN 201510225416 A CN201510225416 A CN 201510225416A CN 106176854 B CN106176854 B CN 106176854B
- Authority
- CN
- China
- Prior art keywords
- babaodan
- liver
- liver injury
- alcoholic liver
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of Babaodan in preparing a medicine for preventing alcoholic liver injury. Pharmacological experiments show that the medicine has obvious effect of preventing alcoholic liver injury. Therefore, the eight-treasure pill can be used for preparing the drug for preventing the alcoholic liver injury and has good development and application prospects.
Description
Technical Field
The invention belongs to the field of new drug indications, and particularly relates to application of Babaodan in preparing a drug for preventing alcoholic liver injury.
Background
alcoholism and alcoholism have become a worldwide problem and are one of the three most serious public health problems listed after cardiovascular and cerebrovascular diseases, cancer, abroad. The clinical symptoms are common: excessive speech, self-burden, irritability, unstable gait, clumsy movement, pale complexion, blurred vision, incoherence, nausea, vomiting, mental retardation, coma and the like. However, few medicines for preventing and treating alcoholism are researched at present, and no effective medicine is available for preventing alcoholism caused by excessive drinking. The development of a medicament for treating alcoholism and alcoholic liver injury with definite curative effect is a problem to be solved urgently.
At present, most of the medicines commonly used for clinically treating alcoholism are diuretics and naloxone. The conventional treatment and symptomatic treatment of western medicine can only relieve partial symptoms, can not remove the continued effect of residual alcohol in the body on the damage of the body, and has very limited effect on preventing liver damage. The traditional Chinese medicine has the advantages of unique effect, integral regulation and small side effect, and increasingly receives attention on treatment of alcoholism, but has the problem of uncertain curative effect, so that the development of a medicine with definite effect on preventing alcoholism liver injury is imperative.
disclosure of Invention
The first purpose of the invention is to provide the application of Babaodan in preparing medicines for preventing alcoholic liver injury according to the current situation that the traditional Chinese medicine composition has the effect of preventing alcoholic liver injury in the research of the traditional Chinese medicine composition.
The BABAODAN is BABAODAN Capsule produced by Xiamen Chinese medicine factory Limited, and has Chinese medicine standard character Z10940006, and comprises calculus bovis, fel Serpentis, cornu Saigae Tataricae, Margarita powder, Notoginseng radix, and Moschus as main ingredients.
The invention relates to an application of Babaodan in preparing a medicine for preventing alcoholic liver injury, which belongs to the first disclosure.
Has the advantages that: the invention has definite and obvious curative effect through preclinical verification. Pharmacological experiments show that the medicine has obvious effect of preventing alcoholic liver injury. Therefore, the eight-treasure pill can be used for preparing the drug for preventing the alcoholic liver injury and has good development and application prospects.
Drawings
FIG. 1 is a bar graph of the intoxication latency of four groups of mice;
FIG. 2 is a bar graph of the time to sober-up for four groups of mice;
FIG. 3 is a bar graph of ALT content in five groups of mice;
FIG. 4 is a bar graph of AST content in five groups of mice;
FIG. 5 is a pathological section of five groups of mice, the magnification of the microscope is X200;
FIG. 6 is a histogram of GSH content of liver homogenate from five groups of mice;
FIG. 7 is a histogram of TG content in liver homogenate from five groups of mice;
FIG. 8 is a bar graph of liver homogenate ADH content in five mice.
Detailed Description
The following examples serve to illustrate the invention.
Dividing 50C 57 mice (weight 25 + -2 g) with age of 8 weeks into 5 groups, which are blank group, model group, low dose group, medium dose group and high dose group, respectively, wherein the blank group is not treated, the other four groups are respectively treated with normal saline, Babaodan low dose, medium dose and high dose intragastric lavage, molding after 1h, and feeding 50% alcohol intragastric lavage according to 12mL/kg dose.
example 1 intoxication latency and sobering time test
The inebriation latency and the time to sober-up were observed for each group of mice. The drunk latency is the time in min from the end of alcohol gastric lavage of the mouse to the occurrence of drunk (unstable crawling, dragging the back abdomen, eye closing, laziness, disappearance of righting reflex). The sobering-up time is the time, unit min, between the mouse's occurrence of intoxication and the mouse's awakening (mobility, flexibility of limbs, mental recovery). The results of the experiment are shown in FIGS. 1 and 2.
remarking: the application dose of Babaodan is as follows: low dose group: 0.125 g/kgBW; the medium dose group: 0.25 g/kgBW; high dose group: 0.5 g/kgBW; model group: 5ml/kgBW physiological saline. The dosage of the Babaodan is the weight of the capsule particle content.
Example 2 serological examination
After the model is made, fasting is not forbidden for drinking for 16h, the eyeballs are picked and blood is taken, centrifugation is carried out at 3000r/min for 10min, serum is separated for detection, and the ALT and AST levels of the serum are measured.
ALT, glutamate pyruvate transaminase, is found primarily in the liver cytoplasm, and damage or necrosis of liver cells raises glutamate pyruvate transaminase in blood. Because the intracellular concentration is 3000 times higher than that of 1000-fold in serum, the serum enzyme can be increased by 1 time as long as 1% of liver cells are necrotic, and the serum enzyme is the most sensitive detection index of liver function damage.
AST, i.e., aspartate aminotransferase, is mainly present in the mitochondria of liver cells and causes an increase in serum concentrations of aspartate aminotransferase when severe necrosis or destruction of the liver occurs.
The degree of ALT and AST elevation is consistent with the degree of hepatocyte damage and is therefore currently the most commonly used indicator of liver function.
The results of the experiment are shown in FIGS. 3 and 4.
Example 3 pathological examination
Mice were sacrificed and left liver lobes were immersed in 4% formaldehyde solution, embedded in paraffin blocks, sectioned, HE stained, fixed, and groups of mice were evaluated for liver pathology. The results are shown in FIG. 5.
Example 4 liver tissue detection
A small piece of liver tissue at the same position of the right lobe of the liver is taken and made into 10 percent liver homogenate by normal saline at 4 ℃, the supernatant is obtained by centrifugation at 2500r/min, and the GSH, TG and ADH activity level of each group of liver tissue is measured.
GSH, reduced glutathione, is present in almost every cell of the body, is the most important non-enzymatic antioxidant in the body, and has the functions of scavenging free radicals and decomposingToxic materials, promoting iron absorption, maintaining the integrity of erythrocyte membrane, maintaining the biosynthesis of DNA, normal growth and development of cells, and cellular immunity. Glutathione is the major non-protein sulfhydryl compound in tissues and is a substrate for two enzymes, GSH-PX and GSH-ST, which are required for the decomposition of hydroperoxides and which stabilize sulfhydryl-containing enzymes and prevent oxidative damage to hemoglobin and other cofactors. GSH is a low molecular scavenger which scavenges O2 -、H2O2LOOH, and thus the amount of GSH is an important factor for measuring the antioxidant capacity of the body.
TG, triglyceride, is the most abundant lipid in the human body, and about 4-7% of lipid-containing substances in hepatocytes, wherein the content of triglyceride is about 1/2, and an excessive content of triglyceride causes fatty liver, and normally, triglyceride synthesized by the liver forms very low density lipoprotein together with phospholipids, cholesterol, and apolipoprotein, and is secreted into the blood. If the phospholipid synthesis disorder or the apolipoprotein synthesis disorder affects the transport of triglyceride out of the liver, fatty liver is caused. In addition, fatty liver may also be caused if the amount of synthesized triglycerides exceeds the ability to synthesize apolipoproteins if there are too many fatty acids entering the liver.
ADH, alcohol dehydrogenase, 95% of which is present in the central region of the liver lobules, 80-90% in the liver cytoplasm, and a small portion in the microparticles. As a key enzyme of main short-chain alcohol metabolism in organisms, in human bodies and mammals, alcohol dehydrogenase and acetaldehyde dehydrogenase (ALDH) form an alcohol dehydrogenase system, participate in-vivo alcohol metabolism and are important metabolic enzymes in human bodies and animals. Alcohol dehydrogenase oxidation systems include Alcohol Dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). The alcohol dehydrogenase alcohol oxidation system is a major pathway for alcohol metabolism in the liver, and the test results are shown in FIGS. 6-8.
the above description is only an embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be made by those skilled in the art without inventive work within the technical scope of the present invention disclosed herein are intended to be covered by the scope of the present invention.
Claims (1)
1. The application of the Babaodan in preparing the medicine for preventing the alcoholic liver injury is disclosed, wherein the Babaodan is a Babaodan capsule produced by Xiamen Chinese medicine factory Limited company, and the Chinese medicine standard Z10940006, and the main components of the Babaodan are bezoar, snake gall, antelope horn, pearl powder, pseudo-ginseng and musk.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510225416.8A CN106176854B (en) | 2015-05-04 | 2015-05-04 | Application of Babaodan in preparing medicine for preventing alcoholic liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510225416.8A CN106176854B (en) | 2015-05-04 | 2015-05-04 | Application of Babaodan in preparing medicine for preventing alcoholic liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106176854A CN106176854A (en) | 2016-12-07 |
| CN106176854B true CN106176854B (en) | 2019-12-17 |
Family
ID=57458956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510225416.8A Active CN106176854B (en) | 2015-05-04 | 2015-05-04 | Application of Babaodan in preparing medicine for preventing alcoholic liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106176854B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857605A (en) * | 2006-04-13 | 2006-11-08 | 孙成山 | Medicine for treating chronic alcoholic hepatopathy and its preparing method |
| CN101695498A (en) * | 2009-10-26 | 2010-04-21 | 昆明理工大学 | Medicament for protecting hepatic injury caused by paracetanol and application thereof |
| CN103830337A (en) * | 2014-03-25 | 2014-06-04 | 崔新明 | Chinese medicinal composition for treating chronic alcoholic toxic liver disease |
-
2015
- 2015-05-04 CN CN201510225416.8A patent/CN106176854B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1857605A (en) * | 2006-04-13 | 2006-11-08 | 孙成山 | Medicine for treating chronic alcoholic hepatopathy and its preparing method |
| CN101695498A (en) * | 2009-10-26 | 2010-04-21 | 昆明理工大学 | Medicament for protecting hepatic injury caused by paracetanol and application thereof |
| CN103830337A (en) * | 2014-03-25 | 2014-06-04 | 崔新明 | Chinese medicinal composition for treating chronic alcoholic toxic liver disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106176854A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | Neuroprotective effect of chlorogenic acid on mitochondrial dysfunction‐mediated apoptotic death of DA neurons in a parkinsonian mouse model | |
| Kabuto et al. | Effects of zingerone [4-(4-hydroxy-3-methoxyphenyl)-2-butanone] and eugenol [2-methoxy-4-(2-propenyl) phenol] on the pathological progress in the 6-hydroxydopamine-induced Parkinson’s disease mouse model | |
| Park et al. | Narirutin fraction from citrus peels attenuates alcoholic liver disease in mice | |
| Shin et al. | Antioxidant and immunostimulating activities of the fruiting bodies of Paecilomyces japonica, a new type of Cordyceps sp. | |
| Lu et al. | Ligustrazine prevents alcohol-induced liver injury by attenuating hepatic steatosis and oxidative stress | |
| JP6355689B2 (en) | Pharmaceutical composition for preventing or treating liver fibrosis or non-alcoholic fatty liver | |
| Lee et al. | Role of mushrooms in neurodegenerative diseases | |
| Virmani et al. | Links between nutrition, drug abuse, and the metabolic syndrome | |
| Ahmed et al. | Enhanced Efficacy of Direct‐Acting Antivirals in Hepatitis C Patients by Coadministration of Black Cumin and Ascorbate as Antioxidant Adjuvants | |
| Liu et al. | Effects of Modified Simiao Decoction on IL‐1β and TNFα Secretion in Monocytic THP‐1 Cells with Monosodium Urate Crystals‐Induced Inflammation | |
| Ng et al. | Green tea catechins as therapeutic antioxidants for glaucoma treatment | |
| CN106176854B (en) | Application of Babaodan in preparing medicine for preventing alcoholic liver injury | |
| Qi et al. | Alpinia oxyphylla–Schisandra chinensis Herb Pair Alleviates Amyloid-β Induced Cognitive Deficits via PI3K/Akt/Gsk-3β/CREB Pathway | |
| Chen et al. | The protective effects of buzui on acute alcoholism in mice | |
| JPS6263517A (en) | Remedy for hepatic disease | |
| CN105963265A (en) | An allantoin preparation and uses thereof | |
| TWI517857B (en) | A pharmaceutical composition for treating senile dementia and a preparation method thereof | |
| CN109224083B (en) | Application of poloxamer-modified iron oxide nanoparticles in preparation of drugs for treating non-alcoholic fatty liver diseases | |
| Ajagun-Ogunleye et al. | Hypoglycemic and high dosage effects of bidens pilosa in type-1 diabetes mellitus | |
| JP2006342073A (en) | Immunoactivity-enhancing ingredient, and food/drink and quasi-drug each containing the same | |
| Liu et al. | Toxic effects of microcystins on the respiratory system | |
| CN112316100B (en) | New use of Rendan traditional Chinese medicine composition for preventing drunk and dispelling effects of alcohol or treating alcoholic liver injury | |
| Dong et al. | Preparation of Dihydromyricetin-Loaded Self-Emulsifying Drug Delivery System and Its Anti-Alcoholism Effect | |
| Aigbiremolen et al. | Morpho-Functional Changes in Cerebellum of Lead II Acetate Exposed, Ocimum gratissimum Administered Wistar Rats | |
| CN109512808B (en) | Application of methyl palmitate in preparation of medicine for preventing or treating fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |